Effects of natalizumab injection: A Synthesis of Findings from 25 Studies

  1. Home
  2. Effects of natalizumab injection
This information is not medical advice and is not a substitute for diagnosis or treatment by a physician.Data sources and disclaimers (data limitations, copyright, etc.)The analysis on "Effects of natalizumab injection: A Synthesis of Findings from 25 Studies" on this page is based on PubMed data provided by the U.S. National Library of Medicine (NLM). However, NLM does not endorse or verify these analyses.

This analysis is based on research papers included in PubMed, but medical research is constantly evolving and may not fully reflect the latest findings. There may also be biases towards certain research areas.

This information is not medical advice and is not a substitute for diagnosis or treatment by a physician. If you have concerns about "Effects of natalizumab injection: A Synthesis of Findings from 25 Studies", please consult your doctor.

For NLM copyright information, please see Link to NLM Copyright Page
PubMed data is obtained via Hugging Face Datasets: Link to DatasetPlease check the disclaimer.
This page's analysis is based on PubMed data provided by the U.S. National Library of Medicine (NLM).
Original Abstract of the Article

Major Research Findings

Natalizumab is a drug used to treat multiple sclerosis. 1 found that some patients experience early relapses after the first dose of natalizumab. 22 showed that natalizumab was previously reserved for patients who didn't respond to or couldn't tolerate other treatments, but with the availability of JC virus antibody testing, it's now being used as a first-line treatment for patients who test negative for the antibodies. Additionally, 16 showed that patients on natalizumab and other immune-modulating medications have different antibody responses to the COVID-19 vaccine. On the other hand, 10 reports a case of a patient on natalizumab developing acute retinal necrosis caused by multiple viruses. This demonstrates that natalizumab's immunosuppressant effect could increase the risk of infection.

Benefits and Risks

Benefits Summary

Natalizumab is expected to have benefits such as reducing the number of relapses, preventing new brain lesions, and treating progressive multiple sclerosis. 22 9 3

Risks Summary

Natalizumab has potential risks including progressive multifocal leukoencephalopathy (PML), infections, and allergic reactions. 9 22 10 1 11 8

Comparison Between Studies

Commonalities Between Studies

Many studies have shown that natalizumab is effective in reducing relapses and preventing new brain lesions in patients with multiple sclerosis. 1 22 9 3 11

Differences Between Studies

There are differences in the administration methods and frequency of natalizumab dosage between studies. Additionally, the risk and frequency of side effects also vary between studies. 1 11 9 3 16 10

Consistency and Discrepancies in Findings

Numerous studies have shown that natalizumab is an effective treatment for multiple sclerosis. However, some studies indicate that some patients experience early relapses after natalizumab administration. Moreover, natalizumab carries the risk of progressive multifocal leukoencephalopathy (PML), so it's essential to use it with caution. 1 22 9 3 11 8

Considerations for Real-World Application

While natalizumab is an effective treatment for multiple sclerosis, it carries the risk of side effects. Therefore, it's crucial to take natalizumab cautiously, following your doctor's instructions. 1 22 9 3 11 8

Limitations of Current Research

Long-term safety and effectiveness data for natalizumab are still limited. Also, research on the combination of natalizumab and other multiple sclerosis treatments is not yet comprehensive. 1 22 9 3 11 8

Future Research Directions

Large-scale clinical trials are necessary to assess the long-term safety and efficacy of natalizumab. Further research is also needed to evaluate the effectiveness of natalizumab in combination with other multiple sclerosis treatments. 1 22 9 3 11 8

Conclusion

Numerous studies have demonstrated the effectiveness of natalizumab in reducing relapses in patients with multiple sclerosis. However, it's crucial to use it cautiously due to the possibility of side effects. Long-term safety and efficacy data for natalizumab are still incomplete. Therefore, consulting with your doctor is vital before starting treatment with natalizumab. 1 22 9 3 11 8

Literature analysis of 25 papers
Positive Content
19
Neutral Content
2
Negative Content
4
Article Type
1
0
0
6
25
1.

Early relapses after the first dose of natalizumab in active multiple sclerosis patients.

Author: CentonzeD, FurlanR, GasperiniC, SalvettiM, BattistiniL

MS treatment
Relapse risk

Natalizumab can precipitate clinical relapses in patients with multiple sclerosis within 24 hours after the first dose.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

2.

Drugs in development for relapsing multiple sclerosis.

Author: AliRehiana, NicholasRichard St John, MuraroPaolo Antonio

Convenient administration
MS treatment
Cardiovascular complications
Macular edema
Progressive multifocal leukoencephalopathy
Secondary autoimmunity
Teratogenicity

Multiple sclerosis (MS) is a challenging disease to treat, with many drugs failing in development. This review discusses recent and developing treatments for relapsing MS, including the pros and cons of each treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

4.

Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.

Author: EagleTessa, StuartFiona, ChuaAlicia S, LaRussaAllison, LeclaireKaitlynne, CookSandra L, ChitnisTanuja, WeinerHoward L, GlanzBonnie I, HealyBrian C

Oral DMT convenience
Side effect reporting

This study compared patients' experiences with and perceptions of injectable, infusion, and oral multiple sclerosis (MS) therapies. Patients reported treatment with the oral medications as more convenient than the injectable and infusion DMTs.

Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Observational StudyResearch that observes and collects data on participants' behavior and outcomes in their natural state, without intervention.

Language : English

8.

Managing adverse effects of disease-modifying agents used for treatment of multiple sclerosis.

Author: MosesHarold, BrandesDavid W

MS treatment
Adverse events

This paper reviews the incidence and management of common adverse events associated with first-line agents for relapsing multiple sclerosis (MS), including interferon beta (IFNbeta)-1a, IFNbeta-1b, glatiramer acetate, mitoxantrone, and natalizumab.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

10.

Acute retinal necrosis caused by co-infection with multiple viruses in a natalizumab-treated patient: a case report and brief review of literature.

Author: CheraqpourKasra, AhmadrajiAliasghar, RashidiniaAli, IrannejadMaziyar, ShahriariMansoor

Acute retinal necrosis

This case report describes a patient with acute retinal necrosis caused by co-infection with herpes simplex virus (type I and II) and varicella-zoster virus (VZV). The patient was also treated with natalizumab for multiple sclerosis. Co-infection with multiple viruses is extremely rare and may be associated with immunosuppressive therapy.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

11.

A safety and pharmacokinetic study of intravenous natalizumab in patients with MS.

Author: SheremataW A, VollmerT L, StoneL A, Willmer-HulmeA J, KollerM

Justifies efficacy studies
Safe and well tolerated

All doses of natalizumab were safe and well tolerated in MS. Serum concentrations of natalizumab are detectable for 3 to 8 weeks after a single 1- or 3-mg/kg IV dose and justify controlled efficacy studies.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Clinical Trial, Phase IThe first stage of clinical trials in humans. Evaluates the safety, tolerability, and pharmacokinetics of a new drug/treatment.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Language : English

12.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.

Author: PortaccioEmilio, AnnovazziPietro, GhezziAngelo, ZaffaroniMauro, MoiolaLucia, MartinelliVittorio, LanzilloRoberta, Brescia MorraVincenzo, RinaldiFrancesca, GalloPaolo, TortorellaCarla, PaolicelliDamiano, PozzilliCarlo, De GiglioLaura, CavallaPaola, CoccoEleonora, MarrosuMaria Giovanna, PattiFrancesco, SolaroClaudio, BellantonioPaolo, UccelliAntonio, LaroniAlice, PastòLuisa, GianniniMarta, TrojanoMaria, ComiGiancarlo, AmatoMaria Pia,

Congenital anomalies
Spontaneous abortion

Natalizumab exposure during pregnancy is associated with an increased risk of spontaneous abortion, but the risk of congenital anomalies requires further investigation.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

14.

An experimental study to evaluate safety/toxicity of intravitreal natalizumab.

Author: ChawlaRohan, NathMadhu, MokshaLaxmi, NagTapas C, VelpandianThirumurthy

Retinal safety
Retinal toxicity

Low-dose and intermediate-dose intravitreal injection of natalizumab appears safe for rabbit retina, but a high-dose injection caused functional and anatomical changes.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

15.

Benefit-Risk Profile of Sphingosine-1-Phosphate Receptor Modulators in Relapsing and Secondary Progressive Multiple Sclerosis.

Author: ComiGiancarlo, HartungHans-Peter, BakshiRajesh, WilliamsIan M, WiendlHeinz

Multiple sclerosis treatment
Side effects

Fingolimod is a drug that is used to treat multiple sclerosis. This study looked at the safety and effectiveness of fingolimod and other similar drugs. The study found that these drugs are effective in treating multiple sclerosis and that their safety profile is suitable for long-term treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : English

16.

Differential antibody response to COVID-19 vaccines across immunomodulatory therapies for multiple sclerosis.

Author: SatyanarayanSammita, SafiNeha, SoretsTali, FilomenaSusan, ZhangYinan, KlineovaSylvia, FabianMichelle, HorngSam, TankouStephanie, MillerAaron, KriegerStephen, LublinFred, SumowskiJames, Katz SandIlana

This study aims to determine the impact of disease-modifying therapies (DMTs) for multiple sclerosis (MS) on antibody response to COVID-19 vaccination. The study will address the limited data available on the immunomodulatory effects of various DMTs and their impact on vaccine efficacy in MS patients.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

17.

[Increased disease activity in a case of multiple sclerosis after switching treatment from fingolimod to natalizumab].

Author: AkataniRitsu, ChiharaNorio, KatanazakaKimitaka, UedaTakehiro, SekiguchiKenji, MatsumotoRiki

MS relapse

This study describes a case of a woman with multiple sclerosis (MS) who experienced worsening of her symptoms after switching from one disease-modifying therapy to another.

Case ReportsIn the medical field, a report that describes in detail a unique case, an unusual medical condition, or the effect of a treatment. Provides new insights and possibilities for treatment through individual patient cases.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : Japanese

18.

Effect of statins on clinical and molecular responses to intramuscular interferon beta-1a.

Author: RudickR A, PaceA, RaniM R S, HydeR, PanzaraM, AppachiS, ShrockJ, MaurerS L, CalabresiP A, ConfavreuxC, GalettaS L, LublinF D, RadueE-W, RansohoffR M

Extremity pain
Fatigue
Hepatic transaminase increase

Statin therapy did not appear to affect the clinical effects of interferon beta-1a in patients with relapsing-remitting multiple sclerosis or the primary molecular response to interferon beta treatment.

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

19.

Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.

Author: PortaccioEmilio, MoiolaLucia, MartinelliVittorio, AnnovazziPietro, GhezziAngelo, ZaffaroniMauro, LanzilloRoberta, Brescia MorraVincenzo, RinaldiFrancesca, GalloPaolo, TortorellaCarla, PaolicelliDamiano, PozzilliCarlo, De GiglioLaura, CavallaPaola, CoccoEleonora, MarrosuMaria Giovanna, SolaroClaudio, UccelliAntonio, LaroniAlice, PastòLuisa, GianniniMarta, TrojanoMaria, ComiGiancarlo, AmatoMaria Pia,

Disease reactivation

Natalizumab suspension during pregnancy in women with multiple sclerosis is associated with a higher relapse rate during and after pregnancy compared to those treated with interferon-β or no treatment.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Language : English

20.

Restrained Th17 response and myeloid cell infiltration into the central nervous system by human decidua-derived mesenchymal stem cells during experimental autoimmune encephalomyelitis.

Author: BravoBeatriz, GallegoMarta I, FloresAna I, BornsteinRafael, Puente-BediaAlba, HernándezJavier, de la TorrePaz, García-ZaragozaElena, Perez-TavarezRaquel, GrandeJesús, BallesterAlicia, BallesterSara

Multiple sclerosis treatment
Side effects

This study explores the therapeutic potential of decidua-derived mesenchymal stem cells (DMSCs) for treating multiple sclerosis, a chronic inflammatory demyelinating disease.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

21.

No difference in radiologic outcomes for natalizumab patients treated with extended interval dosing compared with standard interval dosing: Real-world evidence from MS PATHS.

Author: RyersonLana Zhovtis, NaismithRobert T, KruppLauren B, CharvetLeigh E, LiaoShirley, FisherElizabeth, de MoorCarl, WilliamsJames R, CampbellNolan

Natalizumab EID efficacy

Extended interval dosing (EID) of natalizumab is associated with a lower risk of progressive multifocal leukoencephalopathy compared to standard interval dosing (SID). This study aims to compare MRI outcomes in patients treated with natalizumab EID versus SID and compare MRI outcomes in patients treated with natalizumab (EID and/or SID) versus injectable MS platform therapy.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Language : English

23.

Effects of multiple sclerosis disease-modifying therapies on employment measures using patient-reported data.

Author: ChenJing, TaylorBruce V, BlizzardLeigh, SimpsonSteve, PalmerAndrew J, van der MeiIngrid A F

Improved work attendance
Improved work productivity

This study compared the effects of different disease-modifying therapies (DMTs) on employment outcomes in people with multiple sclerosis (MS). The results suggest that DMTs used in the previous 5 years can improve work attendance, amount of work, and work productivity.

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Language : English

24.

[Multiple sclerosis: current therapies and future perspectives].

Author: MatsushitaTakuya

Delayed MS conversion

Multiple sclerosis (MS) is characterized by demyelination in the central nervous system. While interferon beta and glatiramer acetate have been proven effective, many new disease-modifying therapies are now available, including oral preparations. These treatments target specific immunological reactions, but more research is required to understand long-term side effects and combined effects with existing therapies.

English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Language : Japanese

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.